A Cost Analysis of the Jan Aushadhi Scheme in India
Open Access
- 17 January 2017
- journal article
- Published by Maad Rayan Publishing Company in International Journal of Health Policy and Management
- Vol. 6 (5) , 253-256
Abstract
Medicines constitute a substantial proportion of out-of-pocket (OOP) expenses in Indian households. In order to address this issue, the Government of India launched the Jan Aushadhi (Medicine for the Masses) Scheme (JAS) to provide cheap generic medicines to the patients (http://janaushadhi.gov.in/about_jan_aushadhi.html). These medicines are provided through the Jan Aushadhi stores established across the country. The objective of this study was to do a quick assessment for policy-makers regarding the objective of the JAS. Implications on cost savings for patients and policy implications of the scheme were analyzed. Secondary data sources were used to obtain prices of medicines under the JAS and prices of branded medicines of the same formulations. A cost analysis design was used. There are substantial differences between the JAS price and the cheapest branded medicine available in the market. However, not all JAS prices are lower than branded medicines. For example, the cheapest branded cefuroxime axetil (500 mg) (antibiotic) in the market is almost three times cheaper than its JAS price. Hence, there are cheaper brands available for some commonly prescribed medicines. From the policy perspective, it raises serious questions regarding the pricing of medicines in the JAS and its overarching goal. Since patients are dependent on physicians for medicine prescriptions and have little knowledge of the price variations among branded and generic medicines, the JAS may not provide the cheapest alternative for the patients. Hence, the government should urgently review the JAS prices to achieve its goal of providing low-cost affordable medicines.Keywords
This publication has 8 references indexed in Scilit:
- The crisis in access to essential medicines in India: key issues which call for actionIndian Journal of Medical Ethics, 2013
- Switching from Originator Brand Medicines to Generic Equivalents in Selected Developing Countries: How Much Could Be Saved?Value in Health, 2012
- Access to care and medicines, burden of health care expenditures, and risk protection: Results from the World Health SurveyHealth Policy, 2011
- A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countriesJournal of the International AIDS Society, 2010
- Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug AdministrationAnnals of Pharmacotherapy, 2009
- Encouraging the use of generic medicines: implications for transition economies.2002
- Physicians and the Pharmaceutical Industry: Is a Gift Ever Just a Gift?Obstetrical & Gynecological Survey, 2000
- Physicians and the Pharmaceutical IndustryJAMA, 2000